Teva Saw Record Growth In 2008 Across Key Businesses
This article was originally published in The Pink Sheet Daily
Executive Summary
In contrast to Big Pharma’s doldrums, generics manufacturer Teva had a banner year in 2008 – and expects a strong follow up in 2009.
You may also be interested in...
Teva Continues To Position Itself For Overseas Opportunities
The world economic crisis favors generics, as it puts additional pressure on governments already struggling to contain health care spending and reduce other costs, Teva Pharmaceutical CEO Shlomo Yanai told investors on an earnings call Feb. 17
Teva Continues To Position Itself For Overseas Opportunities
The world economic crisis favors generics, as it puts additional pressure on governments already struggling to contain health care spending and reduce other costs, Teva Pharmaceutical CEO Shlomo Yanai told investors on an earnings call Feb. 17
Generic Drugs Don’t Come Cheap: Teva Buys Barr For $7.46 Billion
Teva's $7.46 billion acquisition of Barr will create an unrivaled generics powerhouse and position the company as a leader in the industry's next untapped frontier: biosimilars